Safety and Efficacy Study of Acthar in Subjects With ARDS
Status:
Withdrawn
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study is being performed to evaluate the potential efficacy and safety of Acthar as a
treatment for moderate-severe Acute Respiratory Distress Syndrome (ARDS). Approximately 210
subjects will be randomized to 1 of 6 possible treatment groups in a 3:2:3:2:3:2 ratio. Study
medication (SM) will be administered via subcutaneous (SC) injection for 4 weeks using a
blinded gradually tapering regimen, and subjects will be followed for 60 days
post-randomization.